

# Elizabeth R Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9233689/publications.pdf>

Version: 2024-02-01

49  
papers

2,647  
citations

430442

18  
h-index

214527

47  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3624  
citing authors

#	ARTICLE	IF	CITATIONS
1	Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State. <i>Clinical Infectious Diseases</i> , 2022, 74, 1089-1092.	2.9	38
2	Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization. <i>Aids</i> , 2022, 36, 257-265.	1.0	6
3	Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057.	13.9	418
4	Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission. <i>Journal of Infectious Diseases</i> , 2022, 226, 225-235.	1.9	4
5	Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. <i>JAMA Network Open</i> , 2022, 5, e2142796.	2.8	57
6	Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	0
7	Detection and kinetics of subgenomic SARS-CoV-2 RNA viral load in longitudinal diagnostic RNA positive samples. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	4
8	Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials. <i>JAMA Network Open</i> , 2022, 5, e2148325.	2.8	24
9	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124.	0.4	25
10	Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	0.9	1
11	Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. <i>Cell Reports Medicine</i> , 2022, 3, 100679.	3.3	100
12	Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 513-520.	2.9	22
13	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	2.0	86
14	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Annals of Internal Medicine</i> , 2021, 174, 344-352.	2.0	73
15	Spatially Weighted Coronary Artery Calcium Score and Coronary Heart Disease Events in the Multi-Ethnic Study of Atherosclerosis. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e011981.	1.3	16
16	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV</i> , 2021, 8, e87-e95.	2.1	70
17	Vaccine optimization for COVID-19: Who to vaccinate first?. <i>Science Advances</i> , 2021, 7, .	4.7	305
18	Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial. <i>AIDS and Behavior</i> , 2021, 25, 2430-2440.	1.4	17

#	ARTICLE	IF	CITATIONS
19	The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence. <i>AIDS and Behavior</i> , 2021, 25, 4169-4179.	1.4	5
20	Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention. <i>AIDS and Behavior</i> , 2021, 25, 2801-2814.	1.4	5
21	Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 46.	3.8	162
22	A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026). <i>AIDS Research and Human Retroviruses</i> , 2021, , .	0.5	5
23	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021, 13, 1921.	1.5	10
24	Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE) Tj ETQq0 0.0,rgBT /Overlock 10	0.7	23
25	Implementation of a fully remote randomized clinical trial with cardiac monitoring. <i>Communications Medicine</i> , 2021, 1, .	1.9	4
26	Brief Report: Anal Intercourse, HIV-1 Risk, and Efficacy in a Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 197-201.	0.9	10
27	Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. <i>Aids</i> , 2020, 34, 559-567.	1.0	3
28	Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities. <i>Statistics in Biosciences</i> , 2020, 12, 468-494.	0.6	5
29	Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIVâ€1 acquisition: a secondary analysis from a randomized, placeboâ€controlled trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25634.	1.2	49
30	Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 475.	0.7	26
31	Joint modeling of time-varying HIV exposure and infection for estimation of per-act efficacy in HIV prevention trials. <i>Statistical Communications in Infectious Diseases</i> , 2020, 12, .	0.2	0
32	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. <i>Lancet HIV,the</i> , 2019, 6, e475-e482.	2.1	19
33	Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial. <i>AJOB Empirical Bioethics</i> , 2019, 10, 79-87.	0.8	3
34	O03.6â€...Vaginal bacteria and risk of incident and persistent infection with high risk sub-types of human papillomavirus. , 2019, , .		0
35	Crossover and Repeated Randomization in Event Driven Trials for HIV Prevention: Addressing the Impact of Heterogeneity in Risk in the Trial Design. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	1
36	Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials. <i>HIV Clinical Trials</i> , 2018, 19, 8-14.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, e8-e10.	0.9	19
38	Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 330-337.	0.9	16
39	Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 73, 606-608.	0.9	81
40	Estimating effectiveness in HIV prevention trials with a Bayesian hierarchical compound Poisson frailty model. <i>Statistics in Medicine</i> , 2016, 35, 2609-2634.	0.8	6
41	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2121-2132.	13.9	624
42	Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. <i>Contraception</i> , 2016, 93, 25-31.	0.8	15
43	Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 335-342.	1.9	40
44	Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. <i>PLoS ONE</i> , 2015, 10, e0128857.	1.1	25
45	High Incidence Is Not High Exposure: What Proportion of Prevention Trial Participants Are Exposed to HIV?. <i>PLoS ONE</i> , 2015, 10, e0115528.	1.1	8
46	Estimating the effectiveness in HIV prevention trials by incorporating the exposure process: Application to HPTN 035 data. <i>Biometrics</i> , 2014, 70, 742-750.	0.8	3
47	Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics. <i>Journal of AIDS &amp; Clinical Research</i> , 2013, 01, .	0.5	16
48	An alternative method for quantifying coronary artery calcification: the multi-ethnic study of atherosclerosis (MESA). <i>BMC Medical Imaging</i> , 2012, 12, 14.	1.4	19
49	Coronary Calcium Coverage Score: Determination, Correlates, and Predictive Accuracy in the Multi-Ethnic Study of Atherosclerosis. <i>Radiology</i> , 2008, 247, 669-675.	3.6	93